Proactiveinvestors USA & Canada Humanigen, Inc. https://ca.proactiveinvestors.com Proactiveinvestors USA & Canada Humanigen, Inc. RSS feed en Tue, 22 Sep 2020 00:27:34 -0400 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) Humanigen prices underwritten public offering of 8 million shares to raise $68M as it preps for Nasdaq debut https://ca.proactiveinvestors.com/companies/news/929447/humanigen-prices-underwritten-public-offering-of-8-million-shares-to-raise-68m-as-it-preps-for-nasdaq-debut-929447.html Fri, 18 Sep 2020 12:28:00 -0400 https://ca.proactiveinvestors.com/companies/news/929447/humanigen-prices-underwritten-public-offering-of-8-million-shares-to-raise-68m-as-it-preps-for-nasdaq-debut-929447.html NA Proactive news snapshot: IEC Electronics, Innocan Pharma, Ion Energy, Alchemist Mining UPDATE ... https://ca.proactiveinvestors.com/companies/news/929128/na-proactive-news-snapshot-iec-electronics-innocan-pharma-ion-energy-alchemist-mining-update--929128.html Tue, 15 Sep 2020 21:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/929128/na-proactive-news-snapshot-iec-electronics-innocan-pharma-ion-energy-alchemist-mining-update--929128.html Humanigen launches public offering of 8 million shares to finance lenzilumab as potential therapy for COVID-19 patients https://ca.proactiveinvestors.com/companies/news/929113/humanigen-launches-public-offering-of-8-million-shares-to-finance-lenzilumab-as-potential-therapy-for-covid-19-patients-929113.html Tue, 15 Sep 2020 12:45:00 -0400 https://ca.proactiveinvestors.com/companies/news/929113/humanigen-launches-public-offering-of-8-million-shares-to-finance-lenzilumab-as-potential-therapy-for-covid-19-patients-929113.html Humanigen and Lonza reveal collaboration to expand manufacturing COVID-19 therapeutic candidate lenzilumab https://ca.proactiveinvestors.com/companies/news/929109/humanigen-and-lonza-reveal-collaboration-to-expand-manufacturing-covid-19-therapeutic-candidate-lenzilumab-929109.html Tue, 15 Sep 2020 12:18:00 -0400 https://ca.proactiveinvestors.com/companies/news/929109/humanigen-and-lonza-reveal-collaboration-to-expand-manufacturing-covid-19-therapeutic-candidate-lenzilumab-929109.html Humanigen says review of lenzilumab Phase 3 study of COVID-19 by data safety monitoring board gets green light to continue https://ca.proactiveinvestors.com/companies/news/928995/humanigen-says-review-of-lenzilumab-phase-3-study-of-covid-19-by-data-safety-monitoring-board-gets-green-light-to-continue-928995.html Mon, 14 Sep 2020 13:23:00 -0400 https://ca.proactiveinvestors.com/companies/news/928995/humanigen-says-review-of-lenzilumab-phase-3-study-of-covid-19-by-data-safety-monitoring-board-gets-green-light-to-continue-928995.html Humanigen plans 1:5 reverse stock split ahead of potential uplisting to Nasdaq exchange https://ca.proactiveinvestors.com/companies/news/928415/humanigen-plans-15-reverse-stock-split-ahead-of-potential-uplisting-to-nasdaq-exchange-928415.html Mon, 07 Sep 2020 11:24:00 -0400 https://ca.proactiveinvestors.com/companies/news/928415/humanigen-plans-15-reverse-stock-split-ahead-of-potential-uplisting-to-nasdaq-exchange-928415.html Humanigen says lenzilumab demonstrated 80% reduction in relative risk of invasive mechanical ventilation and/or death in coronavirus patients https://ca.proactiveinvestors.com/companies/news/927997/humanigen-says-lenzilumab-demonstrated-80-reduction-in-relative-risk-of-invasive-mechanical-ventilation-andor-death-in-coronavirus-patients-927997.html Tue, 01 Sep 2020 13:30:00 -0400 https://ca.proactiveinvestors.com/companies/news/927997/humanigen-says-lenzilumab-demonstrated-80-reduction-in-relative-risk-of-invasive-mechanical-ventilation-andor-death-in-coronavirus-patients-927997.html Humanigen taps drug development expert Edward Jordan for chief commercial officer role ahead of lenzilumab launch https://ca.proactiveinvestors.com/companies/news/927384/humanigen-taps-drug-development-expert-edward-jordan-for-chief-commercial-officer-role-ahead-of-lenzilumab-launch-927384.html Mon, 24 Aug 2020 13:30:00 -0400 https://ca.proactiveinvestors.com/companies/news/927384/humanigen-taps-drug-development-expert-edward-jordan-for-chief-commercial-officer-role-ahead-of-lenzilumab-launch-927384.html Humanigen gets regulatory nod to begin Phase 3 coronavirus trial of lenzilumab in Brazil https://ca.proactiveinvestors.com/companies/news/926261/humanigen-gets-regulatory-nod-to-begin-phase-3-coronavirus-trial-of-lenzilumab-in-brazil-926261.html Mon, 10 Aug 2020 12:55:00 -0400 https://ca.proactiveinvestors.com/companies/news/926261/humanigen-gets-regulatory-nod-to-begin-phase-3-coronavirus-trial-of-lenzilumab-in-brazil-926261.html Humanigen appoints experienced healthcare executive, Bob Atwill to newly created role of Head of Asia-Pacific https://ca.proactiveinvestors.com/companies/news/926039/humanigen-appoints-experienced-healthcare-executive-bob-atwill-to-newly-created-role-of-head-of-asia-pacific-926039.html Thu, 06 Aug 2020 13:06:00 -0400 https://ca.proactiveinvestors.com/companies/news/926039/humanigen-appoints-experienced-healthcare-executive-bob-atwill-to-newly-created-role-of-head-of-asia-pacific-926039.html Humanigen taps biotech veteran Timothy Morris to dual CFO/COO role https://ca.proactiveinvestors.com/companies/news/925707/humanigen-taps-biotech-veteran-timothy-morris-to-dual-cfocoo-role-925707.html Mon, 03 Aug 2020 12:30:00 -0400 https://ca.proactiveinvestors.com/companies/news/925707/humanigen-taps-biotech-veteran-timothy-morris-to-dual-cfocoo-role-925707.html Humanigen chosen by National Institute of Health's upcoming coronavirus clinical trial https://ca.proactiveinvestors.com/companies/news/925620/humanigen-chosen-by-national-institute-of-health-s-upcoming-coronavirus-clinical-trial-925620.html Fri, 31 Jul 2020 14:40:00 -0400 https://ca.proactiveinvestors.com/companies/news/925620/humanigen-chosen-by-national-institute-of-health-s-upcoming-coronavirus-clinical-trial-925620.html Humanigen says lenzilumab selected for National Institute of Health's upcoming coronavirus clinical trial https://ca.proactiveinvestors.com/companies/news/925175/humanigen-says-lenzilumab-selected-for-national-institute-of-health-s-upcoming-coronavirus-clinical-trial-925175.html Mon, 27 Jul 2020 20:32:00 -0400 https://ca.proactiveinvestors.com/companies/news/925175/humanigen-says-lenzilumab-selected-for-national-institute-of-health-s-upcoming-coronavirus-clinical-trial-925175.html Humanigen bolsters partnership with Catalent to produce lenzilumab for coronavirus trials https://ca.proactiveinvestors.com/companies/news/924388/humanigen-bolsters-partnership-with-catalent-to-produce-lenzilumab-for-coronavirus-trials-924388.html Thu, 16 Jul 2020 13:45:00 -0400 https://ca.proactiveinvestors.com/companies/news/924388/humanigen-bolsters-partnership-with-catalent-to-produce-lenzilumab-for-coronavirus-trials-924388.html Humanigen strengthens leadership team with three new executive appointments https://ca.proactiveinvestors.com/companies/news/923647/humanigen-strengthens-leadership-team-with-three-new-executive-appointments-923647.html Tue, 07 Jul 2020 15:35:00 -0400 https://ca.proactiveinvestors.com/companies/news/923647/humanigen-strengthens-leadership-team-with-three-new-executive-appointments-923647.html NA Proactive news snapshot: Milestone Scientific, BetterLife Pharma, Revive Therapeutics, Matinas BioPharma, Biocept UPDATE … https://ca.proactiveinvestors.com/companies/news/923117/na-proactive-news-snapshot-milestone-scientific-betterlife-pharma-revive-therapeutics-matinas-biopharma-biocept-update--923117.html Tue, 30 Jun 2020 21:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/923117/na-proactive-news-snapshot-milestone-scientific-betterlife-pharma-revive-therapeutics-matinas-biopharma-biocept-update--923117.html Humanigen reveals first patient has been infused in ZUMA-19 study https://ca.proactiveinvestors.com/companies/news/923093/humanigen-reveals-first-patient-has-been-infused-in-zuma-19-study-923093.html Tue, 30 Jun 2020 12:30:00 -0400 https://ca.proactiveinvestors.com/companies/news/923093/humanigen-reveals-first-patient-has-been-infused-in-zuma-19-study-923093.html Humanigen says lenzilumab drug delivers better recovery time for coronavirus-associated pneumonia in cross-trial analysis https://ca.proactiveinvestors.com/companies/news/922031/humanigen-says-lenzilumab-drug-delivers-better-recovery-time-for-coronavirus-associated-pneumonia-in-cross-trial-analysis-922031.html Tue, 16 Jun 2020 12:50:00 -0400 https://ca.proactiveinvestors.com/companies/news/922031/humanigen-says-lenzilumab-drug-delivers-better-recovery-time-for-coronavirus-associated-pneumonia-in-cross-trial-analysis-922031.html NA Proactive news snapshot: VR Resources, Ideanomics, AIM ImmunoTech, ImagineAR, Exactus, mCloud Technologies UPDATE … https://ca.proactiveinvestors.com/companies/news/921921/na-proactive-news-snapshot-vr-resources-ideanomics-aim-immunotech-imaginear-exactus-mcloud-technologies-update--921921.html Mon, 15 Jun 2020 21:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/921921/na-proactive-news-snapshot-vr-resources-ideanomics-aim-immunotech-imaginear-exactus-mcloud-technologies-update--921921.html Humanigen sees 12 patients with coronavirus pneumonia recover after lenzilumab treatment in Mayo Clinic study https://ca.proactiveinvestors.com/companies/news/921915/humanigen-sees-12-patients-with-coronavirus-pneumonia-recover-after-lenzilumab-treatment-in-mayo-clinic-study-921915.html Mon, 15 Jun 2020 11:43:00 -0400 https://ca.proactiveinvestors.com/companies/news/921915/humanigen-sees-12-patients-with-coronavirus-pneumonia-recover-after-lenzilumab-treatment-in-mayo-clinic-study-921915.html Humanigen announces 71.8 million dollars in financing https://ca.proactiveinvestors.com/companies/news/921076/humanigen-announces-718-million-dollars-in-financing-921076.html Wed, 03 Jun 2020 18:09:00 -0400 https://ca.proactiveinvestors.com/companies/news/921076/humanigen-announces-718-million-dollars-in-financing-921076.html Humanigen announces pricing of $72M private placement as it advances lenzilumab to treat cytokine storm in coronavirus patients https://ca.proactiveinvestors.com/companies/news/920963/humanigen-announces-pricing-of-72m-private-placement-as-it-advances-lenzilumab-to-treat-cytokine-storm-in-coronavirus-patients-920963.html Tue, 02 Jun 2020 15:26:00 -0400 https://ca.proactiveinvestors.com/companies/news/920963/humanigen-announces-pricing-of-72m-private-placement-as-it-advances-lenzilumab-to-treat-cytokine-storm-in-coronavirus-patients-920963.html Humanigen achieves significant milestone in dosing first coronavirus patient in Phase 3 trial https://ca.proactiveinvestors.com/companies/news/919291/humanigen-achieves-significant-milestone-in-dosing-first-coronavirus-patient-in-phase-3-trial-919291.html Mon, 11 May 2020 14:54:00 -0400 https://ca.proactiveinvestors.com/companies/news/919291/humanigen-achieves-significant-milestone-in-dosing-first-coronavirus-patient-in-phase-3-trial-919291.html NA Proactive news snapshot: Mandalay Resources, OTC Markets Group, Cardiol Therapeutics, Naturally Splendid, Nano One Materials UPDATE ... https://ca.proactiveinvestors.com/companies/news/918997/na-proactive-news-snapshotmandalay-resources-otc-markets-group-cardiol-therapeutics-naturally-splendid-nano-one-materials-update--918997.html Wed, 06 May 2020 21:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/918997/na-proactive-news-snapshotmandalay-resources-otc-markets-group-cardiol-therapeutics-naturally-splendid-nano-one-materials-update--918997.html Humanigen sees first coronavirus patient treated in Phase 3 trial of lenzilumab https://ca.proactiveinvestors.com/companies/news/918986/humanigen-sees-first-coronavirus-patient-treated-in-phase-3-trial-of-lenzilumab-918986.html Wed, 06 May 2020 14:57:00 -0400 https://ca.proactiveinvestors.com/companies/news/918986/humanigen-sees-first-coronavirus-patient-treated-in-phase-3-trial-of-lenzilumab-918986.html NA Proactive news snapshot: VR Resources, LeanLife Health, Loop Insights, Milestone Scientific, Surge Holdings UPDATE … https://ca.proactiveinvestors.com/companies/news/917316/na-proactive-news-snapshot-vr-resources-leanlife-health-loop-insights-milestone-scientific-surge-holdings-update--917316.html Wed, 15 Apr 2020 21:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/917316/na-proactive-news-snapshot-vr-resources-leanlife-health-loop-insights-milestone-scientific-surge-holdings-update--917316.html Humanigen wins FDA nod to commence Phase III study of lenzilumab in coronavirus patients https://ca.proactiveinvestors.com/companies/news/917308/humanigen-wins-fda-nod-to-commence-phase-iii-study-of-lenzilumab-in-coronavirus-patients-917308.html Wed, 15 Apr 2020 12:30:00 -0400 https://ca.proactiveinvestors.com/companies/news/917308/humanigen-wins-fda-nod-to-commence-phase-iii-study-of-lenzilumab-in-coronavirus-patients-917308.html NA Proactive news snapshot: MGX Minerals, Blackrock Gold, Exactus, Enertopia Corporation UPDATE … https://ca.proactiveinvestors.com/companies/news/916510/na-proactive-news-snapshot-mgx-minerals-blackrock-gold-exactus-enertopia-corporation-update--916510.html Thu, 02 Apr 2020 21:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/916510/na-proactive-news-snapshot-mgx-minerals-blackrock-gold-exactus-enertopia-corporation-update--916510.html Humanigen's lenzilumab gets FDA nod for emergency use on compassionate grounds in coronavirus patients https://ca.proactiveinvestors.com/companies/news/916484/humanigen-s-lenzilumab-gets-fda-nod-for-emergency-use-on-compassionate-grounds-in-coronavirus-patients-916484.html Thu, 02 Apr 2020 11:55:00 -0400 https://ca.proactiveinvestors.com/companies/news/916484/humanigen-s-lenzilumab-gets-fda-nod-for-emergency-use-on-compassionate-grounds-in-coronavirus-patients-916484.html Humanigen poised to partner with leading contract research organization on Phase III trial to tackle deadly coronavirus https://ca.proactiveinvestors.com/companies/news/916137/humanigen-poised-to-partner-with-leading-contract-research-organization-on-phase-iii-trial-to-tackle-deadly-coronavirus-916137.html Mon, 30 Mar 2020 17:52:00 -0400 https://ca.proactiveinvestors.com/companies/news/916137/humanigen-poised-to-partner-with-leading-contract-research-organization-on-phase-iii-trial-to-tackle-deadly-coronavirus-916137.html Humanigen moves a step closer to a Phase III trial to tackle leading cause of death in coronavirus https://ca.proactiveinvestors.com/companies/news/915993/humanigen-moves-a-step-closer-to-a-phase-iii-trial-to-tackle-leading-cause-of-death-in-coronavirus-915993.html Fri, 27 Mar 2020 13:55:00 -0400 https://ca.proactiveinvestors.com/companies/news/915993/humanigen-moves-a-step-closer-to-a-phase-iii-trial-to-tackle-leading-cause-of-death-in-coronavirus-915993.html Humanigen appoints David Kovacs to head of public policy for coronavirus issues https://ca.proactiveinvestors.com/companies/news/915695/humanigen-appoints-david-kovacs-to-head-of-public-policy-for-coronavirus-issues-915695.html Tue, 24 Mar 2020 19:55:00 -0400 https://ca.proactiveinvestors.com/companies/news/915695/humanigen-appoints-david-kovacs-to-head-of-public-policy-for-coronavirus-issues-915695.html Humanigen plans Phase III clinical trial for lenzilumab to treat symptoms of coronavirus patients https://ca.proactiveinvestors.com/companies/news/915556/humanigen-plans-phase-iii-clinical-trial-for-lenzilumab-to-treat-symptoms-of-coronavirus-patients-915556.html Mon, 23 Mar 2020 14:41:00 -0400 https://ca.proactiveinvestors.com/companies/news/915556/humanigen-plans-phase-iii-clinical-trial-for-lenzilumab-to-treat-symptoms-of-coronavirus-patients-915556.html Humanigen planning Phase III clinical trial for lenzilumab to treat coronavirus patients; shares soar https://ca.proactiveinvestors.com/companies/news/915443/humanigen-planning-phase-iii-clinical-trial-for-lenzilumab-to-treat-coronavirus-patients-shares-soar-915443.html Fri, 20 Mar 2020 18:02:00 -0400 https://ca.proactiveinvestors.com/companies/news/915443/humanigen-planning-phase-iii-clinical-trial-for-lenzilumab-to-treat-coronavirus-patients-shares-soar-915443.html Humanigen exploring potential therapeutic for lung damage arising from Coronavirus https://ca.proactiveinvestors.com/companies/news/914676/humanigen-exploring-potential-therapeutic-for-lung-damage-arising-from-coronavirus-914676.html Tue, 10 Mar 2020 15:43:00 -0400 https://ca.proactiveinvestors.com/companies/news/914676/humanigen-exploring-potential-therapeutic-for-lung-damage-arising-from-coronavirus-914676.html Humanigen eyes evaluating lenzilumab in treating lung damage caused by coronavirus https://ca.proactiveinvestors.com/companies/news/914568/humanigen-eyes-evaluating-lenzilumab-in-treating-lung-damage-caused-by-coronavirus-914568.html Mon, 09 Mar 2020 13:12:00 -0400 https://ca.proactiveinvestors.com/companies/news/914568/humanigen-eyes-evaluating-lenzilumab-in-treating-lung-damage-caused-by-coronavirus-914568.html Humanigen appoints Korn Ferry senior exec Cheryl Buxton to board https://ca.proactiveinvestors.com/companies/news/909277/humanigen-appoints-korn-ferry-senior-exec-cheryl-buxton-to-board-909277.html Mon, 16 Dec 2019 14:59:00 -0500 https://ca.proactiveinvestors.com/companies/news/909277/humanigen-appoints-korn-ferry-senior-exec-cheryl-buxton-to-board-909277.html Humanigen wins hematological society award for leukemia treatment presentation https://ca.proactiveinvestors.com/companies/news/908986/humanigen-wins-hematological-society-award-for-leukemia-treatment-presentation-908986.html Wed, 11 Dec 2019 14:46:00 -0500 https://ca.proactiveinvestors.com/companies/news/908986/humanigen-wins-hematological-society-award-for-leukemia-treatment-presentation-908986.html Humanigen to present abstracts highlighting its glioblastoma treatments at industry conference https://ca.proactiveinvestors.com/companies/news/906885/humanigen-to-present-abstracts-highlighting-its-glioblastoma-treatments-at-industry-conference-906885.html Tue, 12 Nov 2019 21:11:00 -0500 https://ca.proactiveinvestors.com/companies/news/906885/humanigen-to-present-abstracts-highlighting-its-glioblastoma-treatments-at-industry-conference-906885.html Humanigen’s abstracts on lenzilumab to be presented at the American Society of Hematology https://ca.proactiveinvestors.com/companies/news/906465/humanigens-abstracts-on-lenzilumab-to-be-presented-at-the-american-society-of-hematology-906465.html Wed, 06 Nov 2019 19:05:00 -0500 https://ca.proactiveinvestors.com/companies/news/906465/humanigens-abstracts-on-lenzilumab-to-be-presented-at-the-american-society-of-hematology-906465.html Humanigen updates on its clinical collaboration with Gilead Sciences subsidiary, Kite https://ca.proactiveinvestors.com/companies/news/905471/humanigen-updates-on-its-clinical-collaboration-with-gilead-sciences-subsidiary-kite-905471.html Wed, 23 Oct 2019 18:42:00 -0400 https://ca.proactiveinvestors.com/companies/news/905471/humanigen-updates-on-its-clinical-collaboration-with-gilead-sciences-subsidiary-kite-905471.html Humanigen contemplating raising funds by conducting a broadly syndicated rights offering https://ca.proactiveinvestors.com/companies/news/904859/humanigen-contemplating-raising-funds-by-conducting-a-broadly-syndicated-rights-offering-904859.html Tue, 15 Oct 2019 13:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/904859/humanigen-contemplating-raising-funds-by-conducting-a-broadly-syndicated-rights-offering-904859.html Humanigen Inc finds support for its strategy in treating graft-versus-host disease in medical journal article https://ca.proactiveinvestors.com/companies/news/904394/humanigen-inc-finds-support-for-its-strategy-in-treating-graft-versus-host-disease-in-medical-journal-article-904394.html Tue, 08 Oct 2019 14:15:00 -0400 https://ca.proactiveinvestors.com/companies/news/904394/humanigen-inc-finds-support-for-its-strategy-in-treating-graft-versus-host-disease-in-medical-journal-article-904394.html Humanigen bolsters treatment of graft-versus-host disease in leukemia patients via licensing agreement with the University of Zurich https://ca.proactiveinvestors.com/companies/news/224286/humanigen-bolsters-treatment-of-graft-versus-host-disease-in-leukemia-patients-via-licensing-agreement-with-the-university-of-zurich-224286.html Mon, 22 Jul 2019 20:31:00 -0400 https://ca.proactiveinvestors.com/companies/news/224286/humanigen-bolsters-treatment-of-graft-versus-host-disease-in-leukemia-patients-via-licensing-agreement-with-the-university-of-zurich-224286.html Humanigen inks licensing agreement with the University of Zurich to strengthen its treatment of graft-versus-host disease in leukemia patients https://ca.proactiveinvestors.com/companies/news/314161/humanigen-inks-licensing-agreement-with-the-university-of-zurich-to-strengthen-its-treatment-of-graft-versus-host-disease-in-leukemia-patients-14161.html Mon, 22 Jul 2019 18:18:00 -0400 https://ca.proactiveinvestors.com/companies/news/314161/humanigen-inks-licensing-agreement-with-the-university-of-zurich-to-strengthen-its-treatment-of-graft-versus-host-disease-in-leukemia-patients-14161.html Humanigen teams up with Kite to treat a type of lymphoma cancer https://ca.proactiveinvestors.com/companies/news/313685/humanigen-teams-up-with-kite-to-treat-a-type-of-lymphoma-cancer-13685.html Mon, 10 Jun 2019 18:13:00 -0400 https://ca.proactiveinvestors.com/companies/news/313685/humanigen-teams-up-with-kite-to-treat-a-type-of-lymphoma-cancer-13685.html Humanigen and Gilead's Kite to work on study to evaluate Yescarta with lenzilumab to treat a type of lymphoma https://ca.proactiveinvestors.com/companies/news/221315/humanigen-and-gilead-s-kite-to-work-on-study-to-evaluate-yescarta-with-lenzilumab-to-treat-a-type-of-lymphoma-221315.html Fri, 31 May 2019 14:15:00 -0400 https://ca.proactiveinvestors.com/companies/news/221315/humanigen-and-gilead-s-kite-to-work-on-study-to-evaluate-yescarta-with-lenzilumab-to-treat-a-type-of-lymphoma-221315.html Humanigen's therapy to reduce cancer-treatment side effects highlighted in premier hematology journal https://ca.proactiveinvestors.com/companies/news/220527/humanigen-s-therapy-to-reduce-cancer-treatment-side-effects-highlighted-in-premier-hematology-journal-220527.html Fri, 17 May 2019 14:11:00 -0400 https://ca.proactiveinvestors.com/companies/news/220527/humanigen-s-therapy-to-reduce-cancer-treatment-side-effects-highlighted-in-premier-hematology-journal-220527.html Humanigen unveils promising results from Ifabotuzumab Phase I study at the American Association for Cancer Research's annual meeting https://ca.proactiveinvestors.com/companies/news/217658/humanigen-unveils-promising-results-from-ifabotuzumab-phase-i-study-at-the-american-association-for-cancer-research-s-annual-meeting-217658.html Mon, 01 Apr 2019 08:39:00 -0400 https://ca.proactiveinvestors.com/companies/news/217658/humanigen-unveils-promising-results-from-ifabotuzumab-phase-i-study-at-the-american-association-for-cancer-research-s-annual-meeting-217658.html Humanigen's new data show increase in mice survival with lenzilumab https://ca.proactiveinvestors.com/companies/news/312772/humanigen-s-new-data-show-increase-in-mice-survival-with-lenzilumab-12772.html Thu, 28 Mar 2019 16:56:00 -0400 https://ca.proactiveinvestors.com/companies/news/312772/humanigen-s-new-data-show-increase-in-mice-survival-with-lenzilumab-12772.html Humanigen presents new study showing lenzilumab's potential to fight tumors https://ca.proactiveinvestors.com/companies/news/217031/humanigen-presents-new-study-showing-lenzilumab-s-potential-to-fight-tumors-217031.html Fri, 22 Mar 2019 12:35:00 -0400 https://ca.proactiveinvestors.com/companies/news/217031/humanigen-presents-new-study-showing-lenzilumab-s-potential-to-fight-tumors-217031.html Humanigen CEO optimistic on drug candidate after pulling company from the brink https://ca.proactiveinvestors.com/companies/news/215649/humanigen-ceo-optimistic-on-drug-candidate-after-pulling-company-from-the-brink-215649.html Tue, 05 Mar 2019 19:15:00 -0500 https://ca.proactiveinvestors.com/companies/news/215649/humanigen-ceo-optimistic-on-drug-candidate-after-pulling-company-from-the-brink-215649.html Humanigen pins hopes on monoclonal antibody treatment of cancer therapy's side effects https://ca.proactiveinvestors.com/companies/news/215256/humanigen-pins-hopes-on-monoclonal-antibody-treatment-of-cancer-therapy-s-side-effects-215256.html Mon, 04 Mar 2019 20:25:00 -0500 https://ca.proactiveinvestors.com/companies/news/215256/humanigen-pins-hopes-on-monoclonal-antibody-treatment-of-cancer-therapy-s-side-effects-215256.html Humanigen study of monoclonal antibody in CAR-T therapy presented at Houston conference https://ca.proactiveinvestors.com/companies/news/215241/humanigen-study-of-monoclonal-antibody-in-car-t-therapy-presented-at-houston-conference-215241.html Mon, 25 Feb 2019 14:35:00 -0500 https://ca.proactiveinvestors.com/companies/news/215241/humanigen-study-of-monoclonal-antibody-in-car-t-therapy-presented-at-houston-conference-215241.html Humanigen study of its monoclonal antibody in CAR-T therapy featured in medical journal https://ca.proactiveinvestors.com/companies/news/214733/humanigen-study-of-its-monoclonal-antibody-in-car-t-therapy-featured-in-medical-journal-214733.html Fri, 15 Feb 2019 14:16:00 -0500 https://ca.proactiveinvestors.com/companies/news/214733/humanigen-study-of-its-monoclonal-antibody-in-car-t-therapy-featured-in-medical-journal-214733.html Humanigen has gleaned 'significant' interest from potential partners from its data presentation https://ca.proactiveinvestors.com/companies/news/312185/humanigen-has-gleaned--significant--interest-from-potential-partners-from-its-data-presentation-12185.html Mon, 11 Feb 2019 12:52:00 -0500 https://ca.proactiveinvestors.com/companies/news/312185/humanigen-has-gleaned--significant--interest-from-potential-partners-from-its-data-presentation-12185.html Humanigen new research shows encouraging results for cancer treatment using Car-T https://ca.proactiveinvestors.com/companies/news/311475/humanigen-new-research-shows-encouraging-results-for-cancer-treatment-using-car-t-11475.html Wed, 05 Dec 2018 20:53:00 -0500 https://ca.proactiveinvestors.com/companies/news/311475/humanigen-new-research-shows-encouraging-results-for-cancer-treatment-using-car-t-11475.html Humanigen CEO says company is developing drug to make 'the new frontier' in cancer therapy safer https://ca.proactiveinvestors.com/companies/news/309440/humanigen-ceo-says-company-is-developing-drug-to-make-the-new-frontier-in-cancer-therapy-safer-9440.html Sat, 09 Jun 2018 20:19:00 -0400 https://ca.proactiveinvestors.com/companies/news/309440/humanigen-ceo-says-company-is-developing-drug-to-make-the-new-frontier-in-cancer-therapy-safer-9440.html